吉西他滨单药治疗转移性胰腺癌的药物基因组学分析:GENESECT研究亚组分析
本研究为GENESECT研究的亚组分析,仅纳入50例接受吉西他滨单药治疗的转移性胰腺癌患者,分析药物转运体和代谢酶相关胚系基因多态性与疗效的关系。结果显示ABCC5 1146A>G的AA基因型与更高的CA19-9缓解率相关,DCK -1205T>C的TT/TC基因型与更长的无进展生存期相关,但均需进一步验证。
要点
- ABCC5 1146A>G AA基因型患者CA19-9缓解率高于AG/GG型(52.9% vs 21.2%,p=0.023)。
- DCK -1205T>C TT/TC基因型患者中位PFS显著长于CC型(127 vs 48天,p=0.002)。
- 未发现与总生存期显著相关的基因多态性。
核心结论
- ABCC5和DCK基因多态性可能与吉西他滨单药治疗转移性胰腺癌的疗效相关,但需进一步研究验证。
研究设计与样本
- GENESECT研究的亚组分析,从159例中筛选仅接受吉西他滨单药治疗的患者,最终分析50例。
- 分析基因包括吉西他滨转运体和代谢酶(SLC29A1、ABCC5、CDA、DCK、RRM1/2)及肿瘤细胞增殖酶COX-2。
- 筛选显著性水平为单变量10%,多变量5%。
主要发现
- ABCC5 1146A>G AA基因型患者CA19-9缓解率52.9%,AG/GG型21.2%(p=0.023),多变量分析OR=6.255(p=0.014)。
- ABCC5 1146A>G AA基因型与PFS延长趋势相关但未达显著(HR=0.464,p=0.074)。
- DCK -1205T>C TT/TC基因型患者中位PFS 127天,CC型48天(p=0.002),多变量分析HR=0.153(p=0.028)。
- 未发现任何基因多态性与OS显著相关。
临床怎么用
- 对于接受吉西他滨单药治疗的转移性胰腺癌患者,可关注ABCC5 1146A>G和DCK -1205T>C基因型以评估疗效潜力。
- 目前证据尚不足以指导临床常规基因检测,需等待更大样本研究验证。
局限性
- 样本量较小(仅50例),结论需进一步研究验证。
- 原始GENESECT研究中约70%患者接受联合治疗,可能掩盖单药治疗的遗传关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: In the GENESECT study, no significant gemcitabine (GEM) metabolism-related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab-paclitaxel, which has metabolic pathways different from GEM. The present study was a sub-analysis including only GEM monotherapy patients. METHODS: Of 159 patients analysed in the GENESECT study, only GEM-monotherapy patients were selected. The endpoints included carbohydrate antigen 19-9 (CA19-9) response (reduction ≥ 50% from the pretreatment level at 8 weeks), progression-free survival (PFS), and overall survival (OS) in relation to GPs. Analysed genes included those encoding GEM transporters and metabolic enzymes (SLC29A1, ABCC5, CDA, DCK, RRM1/2) and a tumour cell proliferation enzyme (COX-2). Screening and significance levels were set at 10% (univariable) and 5% (multivariable), respectively. RESULTS: Data for 50 patients were analysed. Genotype AA of ABCC5 1146A>G (rs7636910) showed a higher CA19-9 response rate than AG/GG (52.9% vs. 21.2%, p = 0.023) and remained significant in multivariable analysis (odds ratio: 6.255, p = 0.014). It also tended to be associated with longer PFS, but not significantly (hazard ratio [HR]: 0.464, p = 0.074). By contrast, although CA19-9 responses were not significantly associated with DCK -1205T>C (rs4694362), the TT/TC genotype was significantly associated with prolonged PFS compared with CC (median 127 vs. 48 days, p = 0.002), and this association remained significant in multivariable analysis (HR: 0.153, p = 0.028). No GPs were significantly associated with OS. CONCLUSION: ABCC5 and DCK might be related to the efficacy of GEM treatment, but further research is needed.
引用
- Yokokawa T, Tsuji D, Hatori M, et al. Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study. Br J Clin Pharmacol. 2026. PMID: 42220058. doi:10.1002/bcp.70611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。